Proton pump inhibitor leaflets: Is there information on deprescribing?
Abstract This study aims to analyze the existence of information about deprescription in the leaflets of proton pump inhibitor (PPI) medications. The leaflets available on the Brazilian Health Regulatory Agency (ANVISA) and Food and Drug Administration (FDA) websites for the following medications we...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2025-01-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100805&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592481695301632 |
|---|---|
| author | Marcus Vinícius Lopes Campos Farah Maria Drumond Chequer Luanna Gabriella Resende da Silva André Oliveira Baldoni |
| author_facet | Marcus Vinícius Lopes Campos Farah Maria Drumond Chequer Luanna Gabriella Resende da Silva André Oliveira Baldoni |
| author_sort | Marcus Vinícius Lopes Campos |
| collection | DOAJ |
| description | Abstract This study aims to analyze the existence of information about deprescription in the leaflets of proton pump inhibitor (PPI) medications. The leaflets available on the Brazilian Health Regulatory Agency (ANVISA) and Food and Drug Administration (FDA) websites for the following medications were analyzed: omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. The variables collected in each leaflet were the existence: a) about deprescribing; b) of guidance on the deprescription process; c) maximum recommended time for use; and d) risk of prolonged use. This information was analyzed in accordance with the PPI deprescription guideline, from Canada. Regarding the medication leaflets, 83.33 % from ANVISA and 100 % from the FDA did not present explicit and systematic guidance on deprescribing. Regarding the maximum time of use, 100 % of the leaflets from both agencies contained this information. Regarding the risks of prolonged use of the medication, 33.33 % of the ANVISA leaflets and 33.3 % of the FDA leaflets did not report the increased risks described in the guideline. The results highlight a large gap in information about deprescribing in PPI leaflets; this highlighting is necessary to contribute to the promotion of the rational use of medicines. |
| format | Article |
| id | doaj-art-19fa260294ef4a969fa0454d78ea045d |
| institution | Kabale University |
| issn | 2175-9790 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj-art-19fa260294ef4a969fa0454d78ea045d2025-01-21T07:41:45ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902025-01-016110.1590/s2175-97902025e24168Proton pump inhibitor leaflets: Is there information on deprescribing?Marcus Vinícius Lopes Camposhttps://orcid.org/0009-0004-9129-2025Farah Maria Drumond Chequerhttps://orcid.org/0000-0003-3514-2132Luanna Gabriella Resende da Silvahttps://orcid.org/0000-0003-1879-5166André Oliveira Baldonihttps://orcid.org/0000-0001-6379-0415Abstract This study aims to analyze the existence of information about deprescription in the leaflets of proton pump inhibitor (PPI) medications. The leaflets available on the Brazilian Health Regulatory Agency (ANVISA) and Food and Drug Administration (FDA) websites for the following medications were analyzed: omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. The variables collected in each leaflet were the existence: a) about deprescribing; b) of guidance on the deprescription process; c) maximum recommended time for use; and d) risk of prolonged use. This information was analyzed in accordance with the PPI deprescription guideline, from Canada. Regarding the medication leaflets, 83.33 % from ANVISA and 100 % from the FDA did not present explicit and systematic guidance on deprescribing. Regarding the maximum time of use, 100 % of the leaflets from both agencies contained this information. Regarding the risks of prolonged use of the medication, 33.33 % of the ANVISA leaflets and 33.3 % of the FDA leaflets did not report the increased risks described in the guideline. The results highlight a large gap in information about deprescribing in PPI leaflets; this highlighting is necessary to contribute to the promotion of the rational use of medicines.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100805&lng=en&tlng=enLeafletDeprescriptionRational Use of MedicinesProton Pump InhibitorsBrazilian Health Regulatory Agency (ANVISA)Food and Drug Administration (FDA) |
| spellingShingle | Marcus Vinícius Lopes Campos Farah Maria Drumond Chequer Luanna Gabriella Resende da Silva André Oliveira Baldoni Proton pump inhibitor leaflets: Is there information on deprescribing? Brazilian Journal of Pharmaceutical Sciences Leaflet Deprescription Rational Use of Medicines Proton Pump Inhibitors Brazilian Health Regulatory Agency (ANVISA) Food and Drug Administration (FDA) |
| title | Proton pump inhibitor leaflets: Is there information on deprescribing? |
| title_full | Proton pump inhibitor leaflets: Is there information on deprescribing? |
| title_fullStr | Proton pump inhibitor leaflets: Is there information on deprescribing? |
| title_full_unstemmed | Proton pump inhibitor leaflets: Is there information on deprescribing? |
| title_short | Proton pump inhibitor leaflets: Is there information on deprescribing? |
| title_sort | proton pump inhibitor leaflets is there information on deprescribing |
| topic | Leaflet Deprescription Rational Use of Medicines Proton Pump Inhibitors Brazilian Health Regulatory Agency (ANVISA) Food and Drug Administration (FDA) |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100805&lng=en&tlng=en |
| work_keys_str_mv | AT marcusviniciuslopescampos protonpumpinhibitorleafletsisthereinformationondeprescribing AT farahmariadrumondchequer protonpumpinhibitorleafletsisthereinformationondeprescribing AT luannagabriellaresendedasilva protonpumpinhibitorleafletsisthereinformationondeprescribing AT andreoliveirabaldoni protonpumpinhibitorleafletsisthereinformationondeprescribing |